Malaria—a disease caused by a single-celled parasite—can result in severe headache, high fever, chills, and vomiting. Worldwide, an estimated 300 to 500 million clinical cases of malaria occur each year, and the disease kills more than 1 million children annually.
The parasite is injected into an individual by the bite of an infected mosquito. The nature of the malarial parasite and its means of transmission puts at least 41 percent of the world’s population at risk for malaria infection, making malaria one of the world’s leading health concerns.
Researchers at the NICHD’s Laboratory of Developmental and Molecular Immunity, in partnership with researchers in the Malaria Vaccine Development Branch of the National Institute of Allergy and Infectious Diseases (NIAID), and the Biotechnology Unit of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), have taken a new approach to combating malaria that could have a significant impact on the deadly disease.
A new vaccine could help to eliminate malaria from entire geographic regions, by eradicating the malaria parasite from an area’s mosquitoes. After feeding on the blood of a person who had been vaccinated, the mosquito’s digestive tract would reject the malarial parasite, thus limiting the spread of the disease.
For more information on this finding, read the Malaria Vaccine Prompts Victims' Immune System to Eliminate Parasite From Mosquitoes news release.
For more information on malaria, check out the following resources:
Originally Posted: December 20, 2006
All NICHD Spotlights